SALT LAKE CITY, UT / ACCESS Newswire / October 23, 2025 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2025 financial results that ...
Zacks Investment Research has recently initiated coverage of Utah Medical Products, Inc. UTMD with a Neutral recommendation. This report highlights the company's strong positioning in the growing ...
SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (Nasdaq:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention that insider sales have been known ...
Or for Utah Medical Products: P/E of 27.73 = $94 ÷ $3.39 (Based on the trailing twelve months to September 2018.) Is A High Price-to-Earnings Ratio Good? A higher P/E ratio means that buyers have to ...
The 2Q percentage decline in consolidated revenues was less than for 1H primarily because the period-to-period decline in UTMD sales to its previously major biopharmaceutical OEM customer PendoTECH ...
SALT LAKE CITY, UT / ACCESS Newswire / July 24, 2025 / Utah Medical Products, Inc. [Nasdaq:UTMD] reports second calendar quarter (2Q) and first half (1H) 2025 financial results which are consistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback